Abstract
Background
Steatotic liver disease (SLD) is an emerging liver disease that has been associated with an increased risk for hepatocellular carcinoma (HCC). The impact of concurrent SLD on the prognosis of HCC remains unknown. This study investigates how concurrent SLD affects the outcomes of patients with HCC undergoing curative radiofrequency ablation (RFA) therapy.Methods
A retrospective analysis of patients with early-stage HCC receiving curative RFA at a tertiary medical center was conducted. Laboratory data and HCC characteristics were recorded and analyzed by a Cox proportional hazards regression model to predict recurrence and all-cause mortality after RFA.Results
A total of 598 patients with HCC were included between 2005 and 2015, with 139 and 459 classified in SLD and non-SLD groups, respectively. The SLD group exhibited a significantly better liver reserve and a lower cumulative incidence of HCC recurrence and liver-related and all-cause mortality after a median follow-up of 51 months. After adjusting for metabolic dysfunction, liver reserve, and HCC characteristics, the presence of SLD reduced all-cause mortality (adjusted hazard ratio [aHR], 0.67; 95% confidence interval [CI], 0.45-0.996; p = .048), which was supported by inverse probability weighting analysis (aHR, 0.65; 95% CI, 0.42-1.00; p = .049). Poor liver functional reserve (high albumin-bilirubin grades) increased all-cause mortality dose dependently. Barcelona Clinic Liver Cancer staging and a higher Fibrosis-4 index were predictors for HCC recurrence, whereas SLD was not.Conclusions
Among patients with HCC undergoing curative RFA, those with concurrent SLD had a lower risk of all-cause mortality compared to those with poor liver functional reserve.Plain language summary
The present research demonstrated that patients with both liver cancer and steatotic liver disease who received curative radiofrequency ablation for liver cancer survived longer compared to those without steatotic liver disease. Maintaining good liver function is an important prognostic factor for survival.Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification.
Liver Cancer, 13(5):561-571, 12 Mar 2024
Cited by: 0 articles | PMID: 39435269 | PMCID: PMC11493391
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
Diabetes Metab J, 28 Aug 2024
Cited by: 0 articles | PMID: 39197834
Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma.
Surgeon, 16(3):163-170, 12 Aug 2017
Cited by: 12 articles | PMID: 28807570
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Cochrane Database Syst Rev, 3:CD011650, 28 Mar 2017
Cited by: 52 articles | PMID: 28351116 | PMCID: PMC6464490
Review Free full text in Europe PMC
Funding
Funders who supported this work.
Liver Disease Prevention and Treatment Research Foundation, Taiwan
Ministry of Health and Welfare (1)
Grant ID: MOHW112‐TDU‐B‐221‐124003
Ministry of Health and Welfare, Taiwan (1)
Grant ID: MOHW112-TDU-B-221-124003
National Science and Technology Council, Taiwan (1)
Grant ID: NSTC 112-2628-B-002-004
National Taiwan University Hospital (6)
Grant ID: 113-S0156
Grant ID: 113-TMU09
Grant ID: 113‐S0156
Grant ID: VN-113-04
Grant ID: 113‐TMU09
Grant ID: VN‐113‐04